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Background: Early-onset Group B haemolytic streptococcus infection (EOGBS) is an important cause of neonatal
morbidity and mortality in the first week of life. Primary prevention of EOGBS is possible with intra-partum antibiotic
prophylaxis (IAP.) Different prevention strategies are used internationally based on identifying pregnant women at
risk, either by screening for GBS colonisation and/or by identifying risk factors for EOGBS in pregnancy or labour. A
theoretical cost-effectiveness study has shown that a strategy with IAP based on five risk factors (risk-based
strategy) or based on a positive screening test in combination with one or more risk factors (combination strategy)
was the most cost-effective approach in the Netherlands. IAP for all pregnant women with a positive culture in
pregnancy (screening strategy) and treatment in line with the current Dutch guideline (IAP after establishing a
positive culture in case of pre-labour rupture of membranes or preterm birth and immediate IAP in case of intra-
partum fever, previous sibling with EOGBS or GBS bacteriuria), were not cost-effective. Cost-effectiveness was based
on the assumption of 100% adherence to each strategy. However, adherence in daily practice will be lower and
therefore have an effect on cost-effectiveness.
Method/Design: The aims are to: a.) implement the current Dutch guideline, the risk-based strategy and the
combination strategy in three pilot regions and b.) study the effects of these strategies in daily practice. Regions
where all the care providers in maternity care implement the allocated strategy will be randomised. Before the
introduction of the strategy, there will be a pre-test (use of the current guideline) involving 105 pregnant women
per region. This will be followed by a post-test (use of the allocated strategy) involving 315 women per region. The
outcome measures are: 1.) adherence to the specific prevention strategy and the determinants of adherence
among care providers and pregnant women, 2.) outcomes in pregnant women and their babies and 3.) the costs
of each strategy in relation to the effects.
Discussion: This study will provide recommendations for the implementation of the most cost-effective prevention
strategy for EOGBS in the Netherlands on the basis of feasibility in daily practice.
Trial registration: Dutch Trial Register, NTR3965
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Vertical transmission of the group B haemolytic strepto-
coccus (GBS) during delivery is the main cause of neo-
natal infection in the first week of life and it leads to
early-onset Group B haemolytic streptococcus disease
(EOGBS). EOGBS is an important cause of perinatal
mortality, serious illness and long-term effects for the
baby [1,2]. The mortality rate for children with EOGBS
varies from 9.0 to 10.3% [3-5].
Estimates of the incidence of EOGBS vary between
0.23 and 1.22 per 1000 live births in several European
countries and the USA [6-14]. The estimated incidence
of EOGBS in the Netherlands is based on proven (0.36
per 1000 live births) [13] and probable EOGBS cases
and is 1.9 per 1000 live births [1].
Because of the severe consequences, the importance of
the prevention and mitigation of EOGBS is widely
recognised. Primary prevention of EOGBS is possible
with intra-partum antibiotic prophylaxis (IAP) for preg-
nant women who are GBS carriers. Different prevention
strategies are used internationally based on identifying
mothers at risk, either by screening for maternal colon-
isation with GBS during pregnancy or by identifying risk
factors for EOGBS in pregnancy or during labour.
Established risk factors include the pre-labour rupture of
membranes (> 18 hours), intra-partum fever (≥38.0°C),
preterm birth (<37 weeks), GBS bacteriuria in current
pregnancy and a previous sibling with EOGBS.
However, none of the preventive EOGBS strategies in
place at present result in the complete prevention of
EOGBS, either because the strategy is not fully effective in
itself, or because it has drawbacks which may result in non-
adherence by both care providers and pregnant women.
1. In the risk-based strategy, all women with one or
more of the established risk factors for EOGBS
receive IAP. Care providers are clear about how to
apply this strategy. The effect of the strategy is
limited because over 40% of babies who develop
EOGBS are born to mothers without a risk factor
during pregnancy or labour [13].
2. In the screening strategy, a culture is taken at 35–37
weeks of gestation, and all GBS-colonised women
receive IAP. As with the risk-based strategy, care
providers understand clearly how to apply this
strategy, which is affected by two problems: 1. the
failure of the laboratory to detect GBS in pregnant
women accurately accounts for a consistent
proportion of EOGBS cases [6,15-18] and 2. the
large numbers of women receiving IAP and the
possible negative side-effects such as antibiotic
resistance [6].
3. In the combination strategy, a culture is taken at
35–37 weeks of gestation and women with bothGBS colonisation and one or more of the established
risk factors for EOGBS receive IAP. This strategy
leads to the most accurate use of IAP and therefore
results in the lowest rate of negative side-effects.
However, persistent problems are that laboratories
fail to detect GBS in pregnant women accurately
[6,15-18] and over 40% of babies who develop
EOGBS are born to mothers without a risk factor
during pregnancy or labour [13]. Furthermore,
adherence to this strategy may be affected by
awareness among care providers and pregnant
women of GBS colonisation and this could lead to
an increase in IAP, even in the absence of risk
factors.
4. The current Dutch guideline, which was issued in
1998 [19], prescribes IAP for women with intra-
partum fever, a previous sibling with EOGBS or GBS
bacteriuria during current pregnancy. Cultures are
taken in cases of pre-labour membrane rupture or
preterm birth and IAP is given if GBS colonisation is
established. One of the problems with the Dutch
guideline is that culture results take up to 72 hours to
deliver and cultures are therefore often not yet
available when labour starts. IAP in response to a risk
factor is therefore predominantly based on clinical
observation. The problems mentioned above – the
inaccurate detection of GBS in the combination
strategy [6,15-18] and the fact that over 40% of babies
who develop EOGBS are not born to mothers with
risk factors [6]– are also applicable to the Dutch
guideline.
The effect of the introduction of the Dutch guideline
on the prevention of EOGBS was first evaluated in 2007
[13]. Trijbels et al. reported that the incidence of neo-
natal GBS disease fell hardly at all after the introduction
of the guideline and recommended a change to the na-
tional guideline. In 2005, Van den Akker et al. compared
the cost-effectiveness of the Dutch guideline with the
risk-based strategy, the screening strategy and the com-
bination strategy in a theoretical model [20]. This ana-
lysis took into account the unique maternity care system
in the Netherlands, which involves a 31% home birth rate
and a stratified care model with different professional care
providers at different risk levels. It found that, assuming
100% adherence by care providers and clients, the com-
bination strategy and the risk-based strategy would have
the most favourable cost-effectiveness ratios. The screen-
ing strategy was the most effective, but the least cost-
effective strategy, whereas the Dutch guideline had less ef-
fect but involved even higher costs.
However, the actual impact of any of these four strat-
egies will be the product of efficacy (in other words, to
what extent can the strategy prevent EOGBS?) and the
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is followed by all care providers and all pregnant women).
Full adherence is unlikely in daily practice. There are
many reasons why care providers cannot always observe
guidelines: time constraints, lack of patient cooperation,
lack of self-efficacy, difficult logistical procedures or even
a lack of clear procedures in the guideline, to name just
some examples [21-24].
In 2012, there was a study analysing the determi-
nants of the uptake of the four GBS prevention strat-
egies in the Netherlands mentioned here. The study
looked at care providers and pregnant women by
means of focus group interviews and a subsequent
questionnaire study. As well as identifying the determi-
nants associated with each prevention strategy, the
study found room for improvement in adherence to
the current Dutch guideline, especially in the assess-
ment of clinical risk factors and the process of culture
taking. Furthermore, there was not enough support for
the introduction of the screening strategy. This strat-
egy also turned out not to be cost-effective in the the-
oretical model and so it was decided not to introduce
this strategy in the Netherlands.
The aim of our study is to implement the current
Dutch guideline, the risk-based strategy and combin-
ation strategy, and to study the effects in daily practice.
Our results will support recommendations for the na-
tional implementation of the most cost-effective EOGBS
prevention strategy on the basis of feasibility in daily
practice.
The research questions are:
a. What are the levels of adherence to each prevention
strategy and the determinants of adherence among
care providers and pregnant women?
b. What are the outcomes in pregnant women and
their babies?
c. What are the costs of each prevention strategy and
how do they relate to the effects?Characteristics of the 
Characteristics of the 
Characteristics of the 








Figure 1 Framework representing the innovation process and relatedMethods/Design
Innovation framework
In the present study, we use a framework based on sev-
eral theories that have proven useful in the past for the
introduction and evaluation of innovations – such as
guidelines – in a wide range of settings in Dutch health
care [25-30].
Figure 1 shows the four main stages in innovation pro-
cesses. In the dissemination stage, the innovation should
reach every professional. In the adoption stage, the profes-
sional develops positive or negative intentions about using
the innovation. In the implementation stage, the profes-
sional tries to use the innovation in daily practice and finds
out what working with the innovation actually means. In
the final stage, the continuation stage, working with the
innovation either becomes routine practice or not.
These four main stages in innovation processes can be
thought of as success or failure points at which the de-
sired change may, or may not, occur. The transition
from one stage to the next can be affected, positively or
negatively, by various determinants (see Figure 1). Deter-
minants can be broken down depending on their associ-
ation with:
1. The innovation (determinants such as complexity,
relative advantage, compatibility),
2. The adopting person (determinants such as outcome
expectations, self-efficacy, perceived patient
cooperation),
3. The organisation (determinants such as staff
turnover, financial resources, available time),
4. The socio-political context (determinants such as
legislation) [23,24].
A detailed understanding of determinants helps to de-
sign an innovation strategy that can achieve real change
[23,31-33]. A determinant analysis was performed in
2012 (see Background), resulting in a set of determinants







categories of determinants [23].
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The Dutch EOGBS guideline targets obstetricians, mid-
wives and paediatricians working in the Dutch maternity
care system. This system is a stratified care model with
different professional care providers at different risk
levels. Midwives working in primary care are the main
group of caregivers in low-risk pregnancies. Obstetri-
cians and midwives working in hospitals take care of
medium- or high-risk pregnancies and births. Care path-
ways are organised in Obstetric Collaboration Groups
(OCGs). An OCG is organised around a hospital and
consists of midwives (with independent practices and/or
hospital-based), obstetricians and paediatricians. The
OCGs make agreements about the regional organisation
of maternity care and interdisciplinary collaboration.
Overview of project
This project comprises two main activities: 1). the devel-
opment and application of innovation strategies to en-
hance the uptake of the three prevention strategies in
three study regions and 2). the study of the effects of the
implementation. Before the introduction of the three
prevention strategies in August 2013, a pre-test will be
conducted over a period of three months (March-May
2013). Then, over a period of two months, implementa-
tion activities will take place (June-July 2013). To assess
the effect of the implementation, a post-test will be
performed over a period of six months (August 2013-
January 2014).
Activity 1: Development and application of innovation
strategies
Participants
Three OCG regions will be recruited. Each OCG consists
of one hospital working with three to five midwifery prac-
tices. The EOGBS prevention strategy to be implemented –
the Dutch guideline, the risk-based strategy or the combin-
ation strategy – will be randomly allocated to each region.
All the respondents who participated in the previously
performed determinant analysis (see Background) will be
asked if their OCG is interested in participating in the
study. All the care providers who respond positively will
be approached. The chairpersons of the OCGs in the re-
gion will then be contacted. If participating members of
the OCG express interest, the region will be informed
about the study protocol in an OCG meeting. Inclusion
criteria for participation are:
a. All OCG members have to participate in the study
as the prevention strategy will be implemented in
the entire region. If, for example, one member in the
OCG does not initially support the allocated
prevention strategy, this will have a direct effect on
implementation and the cost-effectiveness.b. The OCG must consist of one hospital and three to
five midwifery practices in primary care in the
vicinity. The number of care providers participating
will be approximately ten midwives in primary care,
five obstetricians, eight to ten hospital-based
midwives and five paediatricians.
c. The OCG must consider collaboration between the
professionals to be good.
Innovation strategies
1. Providing information (enhancing dissemination
and adoption) To enhance awareness of the allocated
prevention strategy, all the care providers will receive a
personal letter and the project will be discussed at sev-
eral regular meetings of the OCG. Furthermore, a pa-
tient information brochure about the prevention strategy
will be developed for distribution by all care providers to
their clients.
2. Recruitment of coordinators (enhancing adoption,
implementation and continuation) Two implementa-
tion coordinators will be assigned to each participating
OCG: a midwife and an obstetrician who introduce and
guide, coordinate and monitor the implementation
process for the allocated prevention strategy. The coor-
dinators will receive coaching throughout the project
from an implementation expert and the project group.
3. Training of professional care providers (enhancing
adoption and implementation) Before the introduction
of the prevention strategy in August 2013, all care providers
will receive training with the aim of optimising the imple-
mentation process. The training will be based on the deter-
minants identified in the determinant analysis performed in
the past. The training consists of three components:
a. General information will be provided about the
theoretical background to EOGBS and its prevention.
There will be a particular focus on correct culture-
taking since considerable variation was found among
care providers in the determinant analysis. The aim is
to train all care providers to the same level.
b. The allocated prevention strategy, and the study
protocol, will be discussed in detail. Potential
barriers to adherence will be discussed and
particular attention will be paid to logistics. The aim
is to clarify and standardise the allocated strategy for
the EOGBS prevention.
c. There will be a particular focus on counselling for
pregnant women, emphasising clear and
unambiguous information about the screening
procedure, the consequences, the administration of
IAP and shared decision-making about treatment
options.
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each prevention strategy
Participants and study design
Before the actual introduction of the three prevention
strategies in August 2013, a pre-test will be conducted
over a period of three months to assess adherence to the
current Dutch guideline. To determine the effects of the
implementation of the three strategies, a post-test will
be performed over a period of six months. During both
the pre-test and post-test, all midwives and obstetricians
will prospectively register all pregnant women from 30
weeks of gestational age onwards. All pregnant women
will receive information about the EOGBS prevention
strategy in their region and permission is acquired on
the basis of opting out [34]. Women who decline to par-
ticipate will be treated in accordance with the current
Dutch guideline. However, pregnant women will be ex-
plicitly asked for permission to take cultures (see out-
come measures) and for IAP in line with the usual
professional standards. Therefore written informed con-
sent will be obtained from all pregnant women.Sample size
To determine adherence to each strategy with sufficient
precision, 315 women are needed (in the case of 70% ad-
herence, the 95% confidence interval will be 65-75%) since
this number will ensure statistical significance at a vari-
ation in adherence of 10% between strategies (alpha = 0.05,
power = 80%).
The pre-test must include 105 pregnant women per
region: 315 in total for the three regions. The post-test
must include 315 pregnant women per region: 945 in
total for the three regions.Adherence and determinants of adherence
Adherence Throughout the study period, adherence to
the key components of each prevention strategy will be
measured for all care providers on the basis of the med-
ical records of all the pregnant women. During the pre-
test, adherence to the current Dutch guideline will be
measured, and adherence to the allocated prevention
strategy will be measured during the post-test. The key
components are: assessment of the clinical risk factors
for EOGBS, culture-taking during pregnancy and during
labour, IAP during labour and treatment of the baby. In
this way, the level of adherence will be measured as the
proportion of all prescribed activities the professional
has actually applied: “completeness of use”. The medical
record search will be performed using standardised
registration forms. Only the combination strategy re-
quires a recto-vaginal culture to be taken from pregnant
women between 35 and 37 weeks by their care provider.
In all prevention strategies the care provider decideswhether IAP is necessary or where there is a contra-
indication for antibiotic prophylaxis.
Determinants At the end of the pre-test (and therefore
prior to the implementation of the innovation strategies)
and at the end of the post-test, all care providers will re-
ceive a questionnaire about the – anticipated – determi-
nants of adherence to the allocated prevention strategy.
The Measuring Instrument for Determinants of Innova-
tions will be used, which consists of 29 generic determi-
nants that predict the actual use of innovations [24].
Outcomes in pregnant women and their babies
Throughout the study period, in the 35th week of preg-
nancy, all women will receive a questionnaire covering
background characteristics, their worries in general and
specifically their worries about EOGBS.
In the first week after birth, all women will receive a
questionnaire covering actual care received and their sat-
isfaction with received care during pregnancy, labour
and the post-partum period.
GBS colonisation of the baby will be used as a proxy
measurement for EOGBS. Cultures will be taken from
315 babies during the pre-test and from 945 babies dur-
ing the post-test.
Clinical outcomes will also be obtained from the med-
ical records: the established risk factors for EOGBS, out-
comes of culture-taking during pregnancy and labour,
IAP during labour, GBS colonisation of the baby, anti-
biotic treatment for the baby, length of hospital stay and
level of hospital care (standard, medium, high). Standar-
dised registration forms will be used to collect the medical
data. Follow-up of the women and children will be one
week after delivery.
Costs of the prevention strategies in relation to the effects
The decision analysis model of the 2005 study [20]
comparing societal costs and the effects of different
prevention strategies will be updated and validated
using the empirical data from the present study. The
costs of implementing the different strategies will also
be incorporated. Sensitivity analyses will vary crucial
model parameters to assess their influence on the cost-
effectiveness ratio.
Analysis
Data will be analysed according to the intention to treat
principle. OCGs will be analysed on the basis of the allo-
cated strategy, regardless of whether the strategy is fully
implemented in the OCG. Base characteristics will be
described. The differences in the outcome percentages
for the pre-test and the post-test will be calculated and
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and regression techniques will be used to evaluate the
effect of the implementation.Ethical consideration
This study is approved by the National Central Committee
on Research involving Human Subjects (CCMO NL
41673.058.12) and by the ethics committee of the Leiden
University Medical Centre (ref. no P12.184). The trial is
registered in the Dutch Trial Register NTR 3965, http://
www.trialregister.nl/trialreg/admin/rctview.asp?TC=3965).Discussion
The effective prevention of EOGBS will be the product
of the efficacy of the applied prevention strategy (to
what extent can the strategy in itself prevent EOGBS)
and the level of implementation (to what extent is the
strategy adhered to by all care providers and all pregnant
women). Since improved adherence may enhance
EOGBS prevention, our study focuses on determinants
that affect adherence to three prevention strategies in
daily practice. The empirical data about adherence will
be used to assess the cost-effectiveness of each strategy
in daily practice.
Although the results will primarily be used for the
national implementation of the most cost-effective
strategy in the Netherlands, the results could be of
interest to health-care professionals, policymakers and
insurance companies in other countries. Regardless of
the prevention strategy used, we expect that other
countries will also have problems with actual adher-
ence. Our determinant analysis found a variation in
adherence to several recommendations of the guide-
line, especially in the assessment of clinical risk fac-
tors and culture-taking procedures. In the United
Kingdom also, considerable variation in the manage-
ment of EOGBS risk prevention was recently reported,
including the application of risk factors and the choice
of antibiotics [35].
Our study has some limitations. Due to the low preva-
lence of EOGBS, a clinical effect study for the detection
of a statistically significant difference in the prevalence
of EOGBS is not feasible. Our study will use the inci-
dence of neonatal colonisation as a proxy measure for
implementation. A second limitation is that the results
may be affected by regional variations. To overcome this
problem we will include regions with minimal differ-
ences in the organisation of maternity care (OCGs) and
population characteristics.
We expect the results of our study to contribute sig-
nificantly to the national and international re-evaluation
of the best strategy for the prevention of EOGBS.Abbreviations
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